CLB101TM Improves Gastrointestinal Symptom Burden in Overweight Adults: A Randomized, Double-Blind, Placebo-Controlled Study
- 1People Science Inc
Abstract
BackgroundAnaerostipes caccae CLB101TM is a next-generation probiotic that directly produces butyrate and is hypothesized to reduce gastrointestinal symptoms by strengthening intestinal barrier integrity. Clinical evidence for A. caccae in symptomatic adult populations remains limited.
MethodsNinety-three adults were randomized 1:1 to CLB101TM (n=47) or placebo (n=46) for 28 days. The primary outcome was safety and tolerability as assessed by the number, frequency, and severity of adverse events. Secondary outcomes were focused on exploring signals of efficacy, and included change in the Gastrointestinal Symptom Rating Scale (GSRS) composite score from baseline to Week 4. Five GSRS subcategories were additionally evaluated. Exploratory endpoints included daily self-reported GI symptoms, as well as stool and blood measures of intestinal barrier function.
Results71 participants were evaluated for the GSRS (77.5% female, aged 42.1 SD 12 years, BMI mean 31.3 SD 3.6). No adverse events were reported in the placebo arm, while three self-limiting adverse events were associated with CLB101TM administration. CLB101TM reduced GI symptom burden versus placebo on the primary GSRS composite at Week 4 (mean change: -1.60 vs -0.90; MWU p=0.040). Two secondary subscales reached significance after FDR-BH correction: Reflux (mean change: -1.26 vs -0.30; FDR-adjusted p=0.024) and Abdominal Pain (mean change: -1.86 vs -0.83; FDR-adjusted p=0.024). Daily symptom diaries showed trends toward greater reductions in abdominal discomfort, bloating, and flatulence in the active arm at the end of study. This study population did not demonstrate signs of intestinal barrier dysfunction. Product adherence averaged 97.7%.
ConclusionsCLB101TM was safe and tolerable and significantly improved overall GI symptom burden, reflux, and abdominal pain after four weeks of daily supplementation in overweight symptomatic adults.
Trial RegistrationThe trial was approved by Sterling IRB (14583-NACraft) and registered with ClinicalTrials.gov (NCT07336615).
Related
- Thymus serpyllum Extract Improves Gastrointestinal Symptoms and Modulates Fecal Gut Microbiome Composition in a Multicenter, Randomized, Placebo-Controlled Clinical Trial.
- AI-facilitated individualized nutritional guidance with ABC-structured prompts improves short-term dietary intake adequacy and patient-reported symptoms after gastrointestinal cancer surgery: a randomized controlled trial.
- A pilot randomized controlled trial of melatonin supplementation on plasma 2-arachidonoylglycerol, ghrelin, and hedonic appetite intensity in females with overweight/obesity
- Effects of a 12-Week Zumba Training Program on Estimated Aerobic Capacity and Exploratory Hematological and Inflammatory Outcomes in Overweight/Obese Postmenopausal Women: A Pilot Randomized Controlled Trial.
- Simulation-based education improves postpartum hemorrhage management knowledge and skills: a randomized controlled trial
BibTeX
@misc{grant2026clb101tm,
title = {{CLB101TM Improves Gastrointestinal Symptom Burden in Overweight Adults: A Randomized, Double-Blind, Placebo-Controlled Study}},
author = {A. D. Grant and B. Meehan and M. C. E. Krupa and M. A. Rosales and K. Sokolowski and B. Newswanger and D. Keller and V. Luna and E. M. S. Valentin and T. McCormick and M. Ghannoum and N. Craft},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.03.26362186},
url = {https://www.medrxiv.org/content/10.64898/2026.09.03.26362186v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - CLB101TM Improves Gastrointestinal Symptom Burden in Overweight Adults: A Randomized, Double-Blind, Placebo-Controlled Study
AU - A. D. Grant
AU - B. Meehan
AU - M. C. E. Krupa
AU - M. A. Rosales
AU - K. Sokolowski
AU - B. Newswanger
AU - D. Keller
AU - V. Luna
AU - E. M. S. Valentin
AU - T. McCormick
AU - M. Ghannoum
AU - N. Craft
PY - 2026
DA - 2026/09/03
PB - medRxiv
DO - 10.64898/2026.09.03.26362186
UR - https://www.medrxiv.org/content/10.64898/2026.09.03.26362186v1
AB - BackgroundAnaerostipes caccae CLB101TM is a next-generation probiotic that directly produces butyrate and is hypothesized to reduce gastrointestinal symptoms by strengthening intestinal barrier integrity. Clinical evidence for A. caccae in symptomatic adult populations remains limited. MethodsNinety-three adults were randomized 1:1 to CLB101TM (n=47) or placebo (n=46) for 28 days. The primary outcome was safety and tolerability as assessed by the number, frequency, and severity of adverse events. Secondary outcomes were focused on exploring signals of efficacy, and included change in the Gastrointestinal Symptom Rating Scale (GSRS) composite score from baseline to Week 4. Five GSRS subcategories were additionally evaluated. Exploratory endpoints included daily self-reported GI symptoms, as well as stool and blood measures of intestinal barrier function. Results71 participants were evaluated for the GSRS (77.5% female, aged 42.1 SD 12 years, BMI mean 31.3 SD 3.6). No adverse events were reported in the placebo arm, while three self-limiting adverse events were associated with CLB101TM administration. CLB101TM reduced GI symptom burden versus placebo on the primary GSRS composite at Week 4 (mean change: -1.60 vs -0.90; MWU p=0.040). Two secondary subscales reached significance after FDR-BH correction: Reflux (mean change: -1.26 vs -0.30; FDR-adjusted p=0.024) and Abdominal Pain (mean change: -1.86 vs -0.83; FDR-adjusted p=0.024). Daily symptom diaries showed trends toward greater reductions in abdominal discomfort, bloating, and flatulence in the active arm at the end of study. This study population did not demonstrate signs of intestinal barrier dysfunction. Product adherence averaged 97.7%. ConclusionsCLB101TM was safe and tolerable and significantly improved overall GI symptom burden, reflux, and abdominal pain after four weeks of daily supplementation in overweight symptomatic adults. Trial RegistrationThe trial was approved by Sterling IRB (14583-NACraft) and registered with ClinicalTrials.gov (NCT07336615).
ER -